H3B-5942

belongs to a class of ERα antagonists referred to as selective estrogen receptor covalent antagonists

Also Known As:

(2E)-4-((2-(4-((1E)-1-(1H-Indazol-5-yl)-2-phenyl-1-buten-1-yl)phenoxy)ethyl)amino)-N,N-dimethyl-2-butenamide; 2-Butenamide, 4-((2-(4-((1E)-1-(1H-indazol-5-yl)-2-phenyl-1-buten-1-yl)phenoxy)ethyl)amino)-N,N-dimethyl-, (2E)-

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - Indazoles: 179
        H3B-5942: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indazoles: 179
      - H3B-5942: 1

Experts

1.	Agoulnik, Sergei: 1 article (01/2018)
2.	Aithal, Kiran: 1 article (01/2018)
3.	Banka, Deepti: 1 article (01/2018)
4.	Bolduc, David M: 1 article (01/2018)
5.	Buonamici, Silvia: 1 article (01/2018)
6.	Caleb, Benjamin: 1 article (01/2018)
7.	Das, Subhasree: 1 article (01/2018)
8.	Eckley, Sean: 1 article (01/2018)
9.	Fekkes, Peter: 1 article (01/2018)
10.	Furman, Craig: 1 article (01/2018)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2018 - "Lastly, H3B-5942 potency can be further improved in combination with CDK4/6 or mTOR inhibitors in both ERαWT and ERαMUT cell lines and/or tumor models. "
2.	Breast Neoplasms (Breast Cancer) 01/01/2018 - "In vivo, H3B-5942 demonstrated significant single-agent antitumor activity in xenograft models representing ERαWT and ERαY537S breast cancer that was superior to fulvestrant. "

Related Drugs and Biologics

1.	MTOR Inhibitors
2.	Antineoplastic Agents (Antineoplastics)
3.	Fulvestrant (Faslodex)